Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

galderma benelux b.v. gravinnen van nassauboulevard 91 4811 bn breda - methylaminolevulinaat hydrochloride samenstelling overeenkomend met ; ; methylaminolevulinaat 160 mg/g - crème - amandelolie ; arachisolie ; cetostearylalcohol ; cholesterol ; dinatriumedetaat 2-water ; glycerol (e 422) ; glycerylmonostearaat, zelf-emulgerend ; isopropylmyristaat ; macrogolstearaat, type i ; methylparahydroxybenzoaat (e 218) ; oleylalcohol ; paraffine, zacht (e 905) ; propylparahydroxybenzoaat ; water, gezuiverd, amandelolie ; arachisolie ; cetostearylalcohol ; cholesterol ; dinatriumedetaat 2-water ; glycerol (e 422) ; glycerylmonostearaat, zelf-emulgerend ; isopropylmyristaat ; macrogolstearaat, type i ; methylparahydroxybenzoaat (e 218) ; oleylalcohol ; paraffine, zacht (e 905) ; propylparahydroxybenzoaat (e 216) ; water, gezuiverd, - methyl aminolevulinate

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

galderma benelux b.v. - methylaminolevulinaathydrochloride 200 mg/g - eq. methylaminolevulinaat 160 mg/g - crème - 160 mg/g - methylaminolevulinaathydrochloride - methyl aminolevulinate

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

methylaminolevulinaat hydrochloride samenstelling overeenkomend met ; ; methylaminolevulinaat - crème - amandelolie ; arachisolie ; cetostearylalcohol ; cholesterol ; dinatriumedetaat 2-water ; glycerol (e 422) ; glycerylmonostearaat, zelf-emulgerend ; isopropylmyristaat ; macrogolstearaat, type i ; methylparahydroxybenzoaat (e 218) ; oleylalcohol ; paraffine, zacht (e 905) ; propylparahydroxybenzoaat (e 216) ; water, gezuiverd

Europese Unie - Nederlands - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevulinezuur hydrochloride - keratosis, actinic; carcinoma, basal cell - antineoplastische middelen - behandeling van actinische keratose van milde tot matige ernst op het gezicht en de hoofdhuid (olsen leerjaar 1 en 2; zie paragraaf 5. 1) en van field cancerization bij volwassenen. behandeling van oppervlakkige en/of nodulair basaalcelcarcinoom ongeschikt voor chirurgische behandeling als gevolg van de mogelijke behandeling gerelateerde morbiditeit en/of slecht cosmetisch resultaat bij volwassenen.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cid lines - chloorhexidinedigluconaat 5 mg/ml - eq. chloorhexidine 2.815 mg/ml - tepeldip oplossing - 5 mg/ml - chloorhexidinedigluconaat 5 mg/ml - chlorhexidine - rund

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cid lines - chloorhexidinedigluconaat 5 mg/ml - eq. chloorhexidine 2.815 mg/ml - tepeldip/tepelspray, oplossing - 5 mg/ml - chloorhexidinedigluconaat 5 mg/ml - chlorhexidine - rund

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

cid lines - chloorhexidine - tepelstift - chloorhexidine 0,5 %, - chlorhexidine - melkkoeien

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

cid lines - chloorhexidinedigluconaat - tepeldip oplossing - chloorhexidinedigluconaat 5 mg/g, - chlorhexidine - melkkoeien

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dr. fisher farma b.v. schutweg 23 8243 pc lelystad - camellia sinensis folium waterig droog extract (24-56 = 1), geËxtraheerd met ethylacetaat en gezuiverd, bevattend een mengsel van 85-95 pct thee catechinen - zalf - isopropylmyristaat ; oleylalcohol ; paraffine, zacht (e 905) ; propyleenglycolmonopalmitostearaat (e 477) ; witte bijenwas (e 901) - sinecatechins

Europese Unie - Nederlands - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.